Core Viewpoint - The company, Kangnibei, anticipates that its export business will account for approximately 8% of total revenue in 2024, focusing on regions such as India, the Middle East, Pakistan, and Europe [2] Group 1 - The export products primarily include active pharmaceutical ingredients such as Azithromycin, Amikacin Sulfate, Dexamethasone Hydrochloride, and Clarithromycin [2]

（文章来源：证券日报） 证券日报网讯 2月12日，康恩贝在互动平台回答投资者提问时表示，公司始终严格按照国家药品监管要 求开展生产经营及产品研发工作，自《中药注册管理专门规定》于2023年发布以来，公司积极响应关于 中药说明书安全性信息标注的要求，系统性启动相关批文的排查与修订工作，公司主要产品均已完成或 正在推进说明书的修订工作，符合相关要求。公司会及时关注政策要求，通过综合评估来开展相应的研 究工作，确保上市品种符合相关规定的要求。 ...

Core Viewpoint - The company is actively advancing its drug development pipeline, focusing on innovation and expanding its product offerings in the pharmaceutical sector [2] Group 1: Drug Development Progress - The company has initiated Phase II clinical trials for EVT401 and a product derived from ivy extract, expected to be completed by the first half of 2025 [2] - The company has received approval for clinical trials of TFA003 tablets, which will be used for treating diabetic kidney disease [2] Group 2: Strategic Focus - The company emphasizes continuous innovation in drug development, generic drug positioning, and secondary development of major products to enhance its product matrix and optimize product structure [2] - The company aims to improve its core competitiveness and sustainable development capabilities through these initiatives [2]

证券日报网讯 2月12日，康恩贝在互动平台回答投资者提问时表示，截至2026年1月31日，公司股东总 户数为80956户。 （文章来源：证券日报） ...

证券简称：康恩贝 证券代码：600572 编号：临 2026-015 浙江康恩贝制药股份有限公司 关于子公司部分药品在国家组织集采药品协议期满品种 接续采购中拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称"公司"）下属子公司杭州康恩贝制药 有限公司、浙江金华康恩贝生物制药有限公司参加了国家组织集采第 1-8 批协议期满品种接 续采购的申报。根据国家组织集采药品协议期满品种接续采购办公室（以下简称"接续采购 办公室"）于 2026 年 2 月 10 日发布的《国家组织集采药品协议期满品种接续采购拟中选结 果表显示，公司盐酸坦索罗辛缓释胶囊、注射用哌拉西林钠他唑巴坦钠、泮托拉唑钠肠溶片 等 11 个药品中选本次接续采购，现将相关情况公告如下： 1 | 8 | 注射用阿奇霉素 | 0.5g | | 适用于敏感病原菌所致的社区获得性肺炎、盆 | | --- | --- | --- | --- | --- | | | | | | 腔炎性疾病。 | | 9 | 盐酸文拉法辛缓释胶囊 ...

Core Viewpoint - Company subsidiaries participated in the national organized procurement for the continuation of drug agreements, with 11 products selected for procurement, indicating a stable revenue stream for the company in the coming years [1][2] Group 1: Procurement Details - The company’s subsidiaries, Hangzhou Kang En Bei Pharmaceutical Co., Ltd. and Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., submitted applications for the national organized procurement continuation [1] - The selected drugs include sustained-release capsules of Tamsulosin Hydrochloride, injectable Piperacillin Sodium and Tazobactam Sodium, and enteric-coated Pantoprazole Sodium, among others [2] Group 2: Financial Impact - The total projected sales revenue from the selected drugs for 2024 is 385.29 million yuan, accounting for 5.91% of the company's total revenue of 6.515 billion yuan [1] - For the first three quarters of 2025, the projected sales revenue from these drugs is 296.15 million yuan, representing 5.95% of the company's revenue of 4.97558 billion yuan [1] Group 3: Pricing Stability - The procurement process is expected to maintain stable or declining prices for the selected drugs, with the procurement quotes for the selected products remaining consistent with their average sales prices in 2025 [2]

Core Viewpoint - Company subsidiaries participated in the national organized procurement for the continuation of drug agreements, with 11 products selected for procurement, indicating a stable revenue stream for the company in the coming years [1][2] Group 1: Procurement Details - The company’s subsidiaries, Hangzhou Kang En Bei Pharmaceutical Co., Ltd. and Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., submitted applications for the national organized procurement continuation [1] - The selected drugs include sustained-release capsules of Tamsulosin Hydrochloride, injectable Piperacillin Sodium and Tazobactam Sodium, and enteric-coated Pantoprazole Sodium tablets among others [1][2] - The expected sales revenue from the selected drugs for 2024 is approximately 385.29 million yuan, accounting for 5.91% of the company's total revenue for that year [1] Group 2: Financial Impact - For the first three quarters of 2025, the total expected sales revenue from the selected drugs is about 296.15 million yuan, representing 5.95% of the company's revenue for that period [1] - The procurement results are expected to be implemented by the end of March 2026, with medical institutions prioritizing the use of selected drugs [2] - The prices of the selected drugs are expected to remain stable or decrease, with procurement quotes maintaining stability compared to the average sales prices in 2025 [2]

Core Insights - The report evaluates the global coenzyme Q10 market for 2026, analyzing data from 126 clinical institutions and over 3 million user feedbacks, focusing on eight major brands' performance in absorption efficiency, raw material purity, clinical support, safety certification, and population adaptability [1] Brand Rankings Brand 1: Qishengtang Coenzyme Q10 - Positioned as a versatile functional nutritional supplement for various demographics, addressing daily health, antioxidant, and immune enhancement needs for individuals aged 25-70, combining high efficacy and safety [3] - Features 99% high-purity ubiquinone, dual authoritative certification, and a zero-additive formula, achieving a bioavailability of 88.7%, which is 120% higher than the industry average [3][4] - The product has a 100% pass rate in SGS testing, adhering to GMP and ISO22000 standards, with a significant user repurchase rate of 92.8% [4] Brand 2: Jiang Yisheng Coenzyme Q10 - Focuses on daily health maintenance with a scientifically formulated blend, suitable for those prioritizing long-term care and safety [5][6] - Holds regulatory certification with a dual antioxidant system, enhancing absorption efficiency and user experience [6] Brand 3: Kang En Bei Coenzyme Q10 - Targets high cost-performance for basic health maintenance, appealing to a broad consumer base aged 25-60 with a focus on convenience and affordability [7] Brand 4: Tong Ren Tang Coenzyme Q10 - Combines traditional health concepts with modern nutrition, designed for all age groups, emphasizing practical use and family-friendly attributes [8] Brand 5: Bao Ying Coenzyme Q10 - Emphasizes gentle formulation and precise care, appealing to young users and those with sensitive constitutions [9] Brand 6: Kirkland Coenzyme Q10 - Leverages a membership retail model for trust, known for high cost-performance and standardized quality control [10] Brand 7: FGHGF Coenzyme Q10 - Focuses on plant-based and gentle formulations, gaining popularity among sensitive and vegetarian consumers [10] Brand 8: bIlvIAyi Coenzyme Q10 - Integrates global research resources, offering a wide product range to meet diverse consumer needs [10] Clinical Validation - Continuous use for 30 days significantly enhances antioxidant capacity, with serum coenzyme Q10 levels increasing by 42.3%, and a 60-day regimen reduces cold incidence by 37.6% [4] - The product's formulation aligns with national daily intake recommendations, containing over 99g of coenzyme Q10 per 100g, far exceeding the industry average of approximately 65% [4] Regulatory Compliance - The product is certified by the National Market Supervision Administration as a health food, meeting domestic compliance requirements, with a price of 119 yuan per box [5]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 一、会议召开和出席情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600572 证券简称：康恩贝 公告编号：2026-013 浙江康恩贝制药股份有限公司 2026年第一次临时股东会决议公告 ■ （四）表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由浙江康恩贝制药股份有限公司（以下简称"公司"）董事会召集，因董事长出差在外，会议 由公司副董事长金军丽主持。本次股东会采取现场会议表决和网络投票表决相结合的方式召开。会议的 召集、召开及表决程序符合《公司法》《公司章程》等相关法律、法规的规定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席6人，董事长应徐颉、非独立董事吴律文、独立董事牛宇龙因出差在外未能 参加本次会议； 2、副总裁、董事会秘书金祖成出席了本次会议，副总裁谌明、尹石水列席本次会议。 二、议案审议情况 （一）非累积投票议案 （一）股东会召开的时间：2026年2月 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2026-014 浙江康恩贝制药股份有限公司 关于股东所持部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）股东胡季强先生现持有本公 司无限售流通股 43,980,005 股，占本公司现总股本 2,536,101,741 股（按 2026 年 2 月 6 日股本 计，下同）的 1.734%；公司持股 5%以上股东及一致行动人康恩贝集团有限公司（以下简称"康 恩贝集团"）、胡季强先生合计持有本公司股份 222,509,556 股，占公司总股本的 8.774%。 2026 年 2 月 9 日，胡季强先生将原质押在中信证券股份有限公司（以下简称"中信证券"） 的本公司 43,180,000 股无限售流通股进行购回并解除质押。截至公告披露日，胡季强先生及康 恩贝集团所持本公司股份没有股份质押。 2026 年 2 月 9 日，公司接股东胡季强先生书面通知，胡季强先生将其质押在中信 证券的本 ...